We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 12, 2021

Chemotherapy ± Avelumab Followed by Avelumab Maintenance vs Chemotherapy Alone in Previously Untreated Epithelial Ovarian Cancer

The Lancet Oncology


Additional Info

The Lancet Oncology
Chemotherapy With or Without Avelumab Followed by Avelumab Maintenance Versus Chemotherapy Alone in Patients With Previously Untreated Epithelial Ovarian Cancer (JAVELIN Ovarian 100): An Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2021 Aug 04;[EPub Ahead of Print], BJ Monk, N Colombo, AM Oza, K Fujiwara, MJ Birrer, L Randall, EV Poddubskaya, G Scambia, YV Shparyk, MC Lim, SM Bhoola, J Sohn, K Yonemori, RA Stewart, X Zhang, J Perkins Smith, C Linn, JA Ledermann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading